Sodium phenylbutyrate-ursodoxicoltaurine for treating amyotrophic lateral sclerosis

Sodium phenylbutyrate-ursodoxicoltaurine is currently in clinical development for amyotrophic lateral sclerosis (ALS), a form of motor neurone disease (MND). ALS is a progressive disease of the nervous system, where nerve cells in the brain and spinal cord that control voluntary movement gradually deteriorate, causing loss of muscle function and paralysis. ALS is a debilitating and life-threatening disease. The gradual loss of neurons leads to a paralysing effect on muscles used for breathing, which usually leads to death from respiratory failure. There is currently no treatment to stop the progression of ALS.